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radiation oncology centers worldwide. We now know that 
these side effects can most often be attributed to the use of 
outdated RT techniques. As treatment techniques started to 
improve, enabling to limit the dose to the organs at risk, 
prospective trials were initiated to evaluate the contribution 
of lymph node treatment to overall outcome for early stage 
breast cancer patients. The results of several studies were 
presented over the last couple of years. They demonstrate 
that an increased disease-free survival rate following a 
decrease of the risk of distant metastases can be obtained in 
patients with risk factors, including those with involvement 
of the axillary lymph nodes and those with a centrally or 
medially located primary tumour. Moreover, a trend towards 
an improved overall and (statistically significant for some of 
the studies) breast cancer specific survival was 
demonstrated. No increase was seen in the other causes of 
death and, at a median follow-up of around 10 years, no 
significant or clinical relevant increased toxicity was found, 
apart from a slight increase in the risk for pulmonary toxicity. 
The concept of “any recurrences”, introduced by the EBCTCG 
in 2011, as important endpoint of the evaluation of the effect 
of all types of treatments (including locoregional ones such as 
surgery and RT) fits much better to the interpretation of the 
recently presented results. In this era of earlier diagnosis and 
more widespread use of adjuvant systemic treatments 
leading to a 10-year overall survival exceeding 80%, clinically 
detectable locoregional recurrences as a separate endpoint 
might indeed be considered as less relevant. Firstly, the 
patient will be affected heavily by any type of recurrence 
and secondly because of the complex interaction between 
the efficacy of systemic treatments with the influence of 
loco-regional treatments on overall survival. By merely 
focusing on locoregional control, we risk to neglect that once 
distant metastases are found no further efforts are 
undertaken to detect locoregional recurrences. 
By eliminating microscopically non-detectable cancer cells in 
the lymph nodes with RT, the risk of secondary metastasizing 
of those cells and thereby ultimately the overall risk of 
recurrence of the breast cancer will be reduced. This is in 
line with the findings of the EORTC trial in which a trend was 
seen towards more benefit for patients who where treated 
with both hormonal treatment and chemotherapy and less 
benefit for the small group of patients with 10 or more 
involved axillary lymph nodes: patients with a better 
prognosis (lower risk factors and/or better systemic therapy) 
experience more benefit from locoregional treatments. With 
modern RT techniques, the benefits of optimizing 
locoregional control will likely not be counterbalanced by 
side effects including late cardiovascular mortality. 
Moreover, the new ESTRO guidelines for target volume 
delineation clearly reduce the size of the target volumes 
while simultaneously considering the regional lymph nodes 
even more than before as a whole. We also expect that the 
real benefit of loco-regional RT used to be diluted in the past 
(including the recently presented trials) by suboptimal dose 
coverage of the target volumes. Therefore, we expect that 
with contemporary RT techniques and appropriate target 
volume delineation, not only a significant reduction of the 
dose to the organs at risk but also a much better coverage of 
especially the internal mammary lymph nodes is achievable, 
which is likely to result in a further improvement of the 
benefit of locoregional RT for patients with early stage breast 
cancer that have a risk for bearing microscopical tumor 
deposits in the regional lymph nodes. 
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The quality of radiotherapeutic approaches to treating 
locoregional lymph nodes in breast cancer is improving. This 
talk will review the latest evidence pertaining to each aspect 
of the planning and treatment pathway in order to inform 
best practice. Recently published atlases capable of 
improving consistency in outlining target and non-target 
volumes will be reviewed. Using data relating outcomes to 
dosimetry, we will then review the evidence base for target 
and non-target tissue dose constraints and objectives. 
Different radiotherapeutic approaches including breath-hold, 
volumetric-modulated arc therapy, and proton beam therapy 
will be compared in terms of dosimetry and resource 
implications. Potential efficiency savings in the treatment 
pathway will also be discussed together with a review of the 
possible impact of bluer-sky technologies. 
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As shown in randomized studies, radiotherapy has a critical 
role when we cure prostate cancer by using multimodal 
treatment strategies. We frequently use radiotherapy to cure 
gynecological cancer. Both Intensity-Modulated Radiation 
Therapy and Volumetric Modulated Arc Therapy have the 
potential to drastically increase the ratio between 
possibilities for cure and risk of late effects. Still, crude 
measurements of patient-reported outcomes, as well as 
factors that may modify the how radiation cause late effects, 
compromise these possibilities. We lack details to provide 
parameters from dose-volume modelling to utilize the full 
potential of these new technologies. Concerning bowel 
health, current scoring systems of radiation-induced late 
gastrointestinal must be refined. Important socially 
invalidating symptoms are not scored. An example is 
unexpected defecation into clothing – not sensing the need to 
go to the toilet and a sudden defecation into clothing as if 
one were already on the toilet. We documented this 
symptom among 11 percent of gynecological-cancer 
survivors. Another example is frequent and uncontrolled 
noisy flatulence. Traditional scoring systems have scales that 
do not distinguish or clearly depict person-incidence (events 
per individual per time unit), intensity and duration. But, 
probably most important, as we learn that decreased bowel 
health depends on several different types of radiation-
induced illness, we understand that grouping symptoms from 
different illnesses together in a score compromises our ability 
to acquire knowledge for prevention or relief. We cannot 
disentangle these different radiation-induced illnesses when 
symptoms from several illnesses are grouped together in the 
data sets we retrieve. Clearly, new strategies are needed. In 
my talk, I will propose a scoring system based on the data 
indicating that the at least 28 radiotherapy-induced atomized 
late gastrointestinal symptoms derive from six distinct 
illnesses, that is, six sets of risk organs or mechanisms. We 
have data from around 1500 survivors supporting this 
position. As we accumulate data for each of these six 
illnesses, we can define parameters in dose-volume models 
built on patient-reported outcomes much better than we 
previously could. Possibly we can also learn how, by 
employing probiotics or dietary changes, we can influence 
the interplay between the gut flora and stem-cell renewal to 
counteract inflammatory processes that probably are 
important for several of the six illnesses. Moreover, the 
knowledge may stimulate development of mouse models in 
which we can test, for example, how different bacterial 
species influence radiation-induced inflammation in the 
rectal wall. In the talk, I will give preliminary results from 
the establishment of such a model. A simplified 
nomenclature could label the six illnesses as involving 
processes resulting in leakage-related symptoms, urgency-
related symptoms, constipation-related symptoms, symptoms 
